Previous Article | Next Article ![]()
Infection and Immunity, October 2001, p. 6364-6369, Vol. 69, No. 10
Pulmonary and Critical Care Medicine, The
University of Michigan Medical School,1 and
Environmental Health Sciences, University of Michigan School of
Public Health,2 Ann Arbor, Michigan
Received 25 April 2001/Returned for modification 14 June
2001/Accepted 10 July 2001
The objective of these studies was to determine the role of
macrophage inflammatory protein 1
0019-9567/01/$04.00+0 DOI: 10.1128/IAI.69.10.6364-6369.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Macrophage Inflammatory Protein 1
/CCL3 Is Required for
Clearance of an Acute Klebsiella pneumoniae Pulmonary
Infection
/CCL3 in pulmonary host
defense during Klebsiella pneumoniae infection. Following
intratracheal inoculation, 7-day survival of CCL3
/
mice
was less than 10%, compared to 60% for CCL3+/+ mice.
Survival of CCR5
/
mice was equivalent to that of
controls, indicating that the enhanced susceptibility of
CCL3
/
mice to K. pneumoniae is mediated via
another CCL3 receptor, presumably CCR1. At day 3, CFU burden in the
lungs of CCL3
/
mice was 800-fold higher than in
CCL3+/+ mice, demonstrating that CCL3 is critical for
control of bacterial growth in the lung. Surprisingly,
CCL3
/
mice had no differences in the recruitment of
monocytes/macrophages and even showed enhanced neutrophil
recruitment at days 1, 2, and 3 postinfection, compared to
CCL3+/+ mice. Therefore, the defect in clearance was not
due to insufficient recruitment of leukocytes. No significant
differences in cytokine levels of monocyte chemoattractant protein 1 (MCP-1), interleukin 12, gamma interferon, or tumor necrosis
factor alpha in lung lavages were found between CCL3+/+ and
CCL3
/
mice. CCL3
/
alveolar
macrophages were found to have significantly lower phagocytic activity toward K. pneumoniae than CCL3+/+
alveolar macrophages. These findings demonstrate that CCL3
production is critical for activation of alveolar macrophages
to control the pulmonary growth of the gram-negative bacterium K. pneumoniae.
*
Corresponding author. Mailing address: Pulmonary and
Critical Care Medicine, 6301 MSRB III, University of Michigan Medical Center, Ann Arbor, MI 48109-0642. Phone: (734) 936-9369. Fax: (734)
764-4556. E-mail: ghuff{at}umich.edu.
This article has been cited by other articles:
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|